Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca's Bydureon BCise Gets U.S. Approval For Type 2 Diabetes in Pediatric Patients

07/23/2021 | 06:26am EDT

By Michael Dabaie

AstraZeneca said its Bydureon BCise, or exenatide extended-release, was approved in the U.S. for the treatment of type 2 diabetes in pediatric patients ages 10 years and older.

The U.S. Food and Drug Administration approval was supported by the results of the BCB114 Phase III trial in youth with type 2 diabetes. which showed on top of standard of care exenatide extended-release significantly improved glycemic control compared to placebo in pediatrics.

Bydureon BCise was first approved in the U.S. in October 2017 as a once-weekly single-dose autoinjector device to improve glycemic control for adults with type 2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise. It was also approved for use in the European Union in August 2018.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

07-23-21 0826ET

All news about ASTRAZENECA PLC
06:06aHealth Ministry - Four Covid-19 Vaccines Now Available in Sudan
AQ
05:13aLONDON STOCK EXCHANGE : Inflation and China fears weigh on UK markets
09/15ASTRAZENECA : Panama to hand out AstraZeneca vaccines to visitors in tourism pus..
RE
09/15INDONESIA IN TALKS WITH WHO TO BECOM : minister
RE
09/15China's biotech sector comes of age with big licensing deals, global ambition..
RE
09/15ASTRAZENECA : JP Morgan reiterates its Buy rating
MD
09/15ASTRAZENECA : UBS reaffirms its Buy rating
MD
09/15ASTRAZENECA : India considers resuming vaccine exports soon, focus on Africa, sa..
RE
09/14UK Medicines Regulator Clears Moderna's COVID-19 Jab for Booster Program
MT
09/14CORONAVIRUS : South Sudan receives its first consignment of Johnson & Johnson CO..
AQ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 166 M - -
Net income 2021 4 990 M - -
Net Debt 2021 24 654 M - -
P/E ratio 2021 22,9x
Yield 2021 3,46%
Capitalization 126 B 174 B -
EV / Sales 2021 4,29x
EV / Sales 2022 3,44x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 81,41 $
Average target price 136,09 $
Spread / Average Target 67,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC10.94%174 207
JOHNSON & JOHNSON5.11%435 465
ROCHE HOLDING AG11.23%327 497
PFIZER, INC.21.46%251 011
NOVO NORDISK A/S49.16%231 607
ELI LILLY AND COMPANY38.43%211 895